-
A massive real-world study comparing tirzepatide and semaglutide reveals both drugs deliver strong, early cardiovascular protection—reducing heart attack, stroke, and death in adults with type 2 diabetes. While companies have claimed large differences favoring their own medications, researchers found only modest distinctions between the two blockbuster GLP-1 drugs.
-
Researchers uncovered how estrogen subtly reshapes learning by strengthening dopamine reward signals in the brain. Rats learned faster when estrogen levels were high and struggled when the hormone’s activity was blocked. The findings help explain how hormonal cycles influence cognitive performance and psychiatric symptoms. This connection offers a new path for understanding brain disorders tied to dopamine.
-
Researchers discovered that the common amino acid arginine can block harmful Aβ aggregation and reduce its toxic effects in Alzheimer’s disease models. In flies and mice, oral arginine lowered plaque levels, reduced inflammation, and improved behavior. Its strong safety record and low cost make it a promising repurposing candidate. The findings hint at a surprisingly simple path toward more accessible AD therapies.
-
Researchers discovered that chemotherapy can accidentally trigger a stress alarm in immune cells, causing inflammation that damages nerves. Blocking this alarm protected mice from nerve pain and kept their nerves healthier. A drug already being tested for cancer may help do the same in people. Early blood tests suggest it may even be possible to predict who will develop these symptoms before they happen.
-
A new airflow device from UBC Okanagan engineers traps exhaled aerosols almost immediately, sharply reducing pathogen exposure in indoor spaces. Early simulations suggest it could outperform existing ventilation systems by a wide margin.
